Throughout the entire clinical development, who has the most interaction with prospective and active subjects? Who is primarily responsible for the quality of the source data that ultimately decides the approvability of all biopharmaceutical products?
Throughout the entire clinical development, who has the most interaction with prospective and active subjects? Who is primarily responsible for the quality of the source data that ultimately decides the approvability of all biopharmaceutical products?
Principal investigators were asked who satisfaction surveys should focus on during a study. Site Coordinators were named more than half the time, ahead of PIs themselves.
Yes, the answers are identical: the site coordinator, study coordinator, or clinical research coordinator, whatever title you choose. These individuals are the keystone, the glue that holds the study process together. Without them very few patients would be randomized, informed consent forms would not be completed, site contracts would not be negotiated, data would not be entered, queries would not get resolved, and database lock would be delayed.
Delay is the key point. Site coordinators help a study stay on track. Without good ones, hitting milestones would be nearly impossible.
ISR dedicated an entire study (The Voice of the Site Coordinator— www.isrreports.com/reports) to understanding site coordinator's experiences and perspectives on improving the success of clinical trials.
—Industry Standard Research
Industry Assessment of Risk-Based Quality Management Emphasizes Value of Adoption
April 4th 2024A study conducted by the Tufts CSDD in collaboration with CluePoints and PwC revealed that slightly more than half of sponsors and contract research organizations have adopted risk-based quality management approaches.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.